SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. [electronic resource]
Producer: 20210331Description: 1472-1482 p. digitalISSN:- 1468-3288
- Aged
- Animals
- Apoptosis
- Carcinoma, Pancreatic Ductal -- drug therapy
- Cell Line, Tumor
- Cell Proliferation
- Enzyme Inhibitors -- pharmacology
- Esters -- pharmacology
- Female
- Gene Amplification
- Gene Expression
- Humans
- Male
- Mice
- Middle Aged
- Neoplasm Transplantation
- Organoids -- metabolism
- Pancreatic Neoplasms -- drug therapy
- Prognosis
- Proto-Oncogene Proteins c-myc -- genetics
- Pyrazoles -- pharmacology
- Pyrimidines -- pharmacology
- SUMO-1 Protein -- genetics
- Small Ubiquitin-Related Modifier Proteins -- genetics
- Sulfonic Acids
- Sumoylation -- drug effects
- Transcriptome -- drug effects
- Ubiquitin-Activating Enzymes -- antagonists & inhibitors
- Ubiquitin-Conjugating Enzymes -- genetics
- Ubiquitins -- genetics
- Ubiquitin-Conjugating Enzyme UBC9
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.